Copyright Reports & Markets. All rights reserved.

Global Rapid Acting Insulins Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Rapid Acting Insulins Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Lispro
      • 1.4.3 Aspart (NovoLog)
      • 1.4.4 Glulisine (Apidra)
    • 1.5 Market by Application
      • 1.5.1 Global Rapid Acting Insulins Market Share by Application (2014-2025)
      • 1.5.2 Type 1 Diabetes
      • 1.5.3 Type 2 Diabetes
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Rapid Acting Insulins Market Size
    • 2.2 Rapid Acting Insulins Growth Trends by Regions
      • 2.2.1 Rapid Acting Insulins Market Size by Regions (2014-2025)
      • 2.2.2 Rapid Acting Insulins Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Rapid Acting Insulins Market Size by Manufacturers
      • 3.1.1 Global Rapid Acting Insulins Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Rapid Acting Insulins Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Rapid Acting Insulins Market Concentration Ratio (CR5 and HHI)
    • 3.2 Rapid Acting Insulins Key Players Head office and Area Served
    • 3.3 Key Players Rapid Acting Insulins Product/Solution/Service
    • 3.4 Date of Enter into Rapid Acting Insulins Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Rapid Acting Insulins Market Size by Type (2014-2019)
    • 4.2 Global Rapid Acting Insulins Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Rapid Acting Insulins Market Size (2014-2019)
    • 5.2 Rapid Acting Insulins Key Players in United States
    • 5.3 United States Rapid Acting Insulins Market Size by Type
    • 5.4 United States Rapid Acting Insulins Market Size by Application

    6 Europe

    • 6.1 Europe Rapid Acting Insulins Market Size (2014-2019)
    • 6.2 Rapid Acting Insulins Key Players in Europe
    • 6.3 Europe Rapid Acting Insulins Market Size by Type
    • 6.4 Europe Rapid Acting Insulins Market Size by Application

    7 China

    • 7.1 China Rapid Acting Insulins Market Size (2014-2019)
    • 7.2 Rapid Acting Insulins Key Players in China
    • 7.3 China Rapid Acting Insulins Market Size by Type
    • 7.4 China Rapid Acting Insulins Market Size by Application

    8 Japan

    • 8.1 Japan Rapid Acting Insulins Market Size (2014-2019)
    • 8.2 Rapid Acting Insulins Key Players in Japan
    • 8.3 Japan Rapid Acting Insulins Market Size by Type
    • 8.4 Japan Rapid Acting Insulins Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Rapid Acting Insulins Market Size (2014-2019)
    • 9.2 Rapid Acting Insulins Key Players in Southeast Asia
    • 9.3 Southeast Asia Rapid Acting Insulins Market Size by Type
    • 9.4 Southeast Asia Rapid Acting Insulins Market Size by Application

    10 India

    • 10.1 India Rapid Acting Insulins Market Size (2014-2019)
    • 10.2 Rapid Acting Insulins Key Players in India
    • 10.3 India Rapid Acting Insulins Market Size by Type
    • 10.4 India Rapid Acting Insulins Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Rapid Acting Insulins Market Size (2014-2019)
    • 11.2 Rapid Acting Insulins Key Players in Central & South America
    • 11.3 Central & South America Rapid Acting Insulins Market Size by Type
    • 11.4 Central & South America Rapid Acting Insulins Market Size by Application

    12 International Players Profiles

    • 12.1 Eli Lilly
      • 12.1.1 Eli Lilly Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Rapid Acting Insulins Introduction
      • 12.1.4 Eli Lilly Revenue in Rapid Acting Insulins Business (2014-2019)
      • 12.1.5 Eli Lilly Recent Development
    • 12.2 Novo Nordisk
      • 12.2.1 Novo Nordisk Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Rapid Acting Insulins Introduction
      • 12.2.4 Novo Nordisk Revenue in Rapid Acting Insulins Business (2014-2019)
      • 12.2.5 Novo Nordisk Recent Development
    • 12.3 Sanofi
      • 12.3.1 Sanofi Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Rapid Acting Insulins Introduction
      • 12.3.4 Sanofi Revenue in Rapid Acting Insulins Business (2014-2019)
      • 12.3.5 Sanofi Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Rapid Acting Insulins are usually taken before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating. Rapid acting insulins can be used for both type 1 and type 2 diabetes, injected or delivered via an insulin pump.
      In 2018, the global Rapid Acting Insulins market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Rapid Acting Insulins status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Rapid Acting Insulins development in United States, Europe and China.

      The key players covered in this study
      Eli Lilly
      Novo Nordisk
      Sanofi
      ...

      Market segment by Type, the product can be split into
      Lispro
      Aspart (NovoLog)
      Glulisine (Apidra)

      Market segment by Application, split into
      Type 1 Diabetes
      Type 2 Diabetes

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Rapid Acting Insulins status, future forecast, growth opportunity, key market and key players.
      To present the Rapid Acting Insulins development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Rapid Acting Insulins are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now